SCHEMBL2366675

SCHEMBL2366675

CCOCC1COC(=O)N1c1ccc(C(=O)N2CCN(c3ncc(C4CC4)cc3C3CC3)CC2)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
KMT2A Q03164 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
NTSR1 P30989 1/20 0.34
SLC6A7 Q99884 1/20 0.34
EGLN1 Q9GZT9 3/20 0.34
DGAT1 O75907 1/20 0.34
ALOX15 P16050 1/20 0.34
GAA P10253 1/20 0.34
MEN1 O00255 3/20 0.33
ALDH1A1 P00352 2/20 0.33
DCTPP1 Q9H773 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
SSTR5 P35346 1/20 0.33
P2RY12 Q9H244 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366668 1.00 LMNA (0.35) LMNAKMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL2366766 0.93 LMNA (0.37) LMNAKMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL2366761 0.93 LMNA (0.37) LMNAKMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL2366005 0.92 EGLN1 (0.36) LMNAKMT2AMAPTNTSR1SLC6A7
SCHEMBL2366014 0.92 EGLN1 (0.36) LMNAKMT2AMAPTNTSR1SLC6A7
SCHEMBL2365950 0.92 P2RX3 (0.37) KMT2ASMN1; SMN2KDM4EMAPTNTSR1
SCHEMBL2365943 0.92 P2RX3 (0.37) KMT2ASMN1; SMN2KDM4EMAPTNTSR1
SCHEMBL2366048 0.89 SLC6A7 (0.37) SMN1; SMN2KDM4ENTSR1SLC6A7EGLN1
SCHEMBL2366074 0.89 SLC6A7 (0.37) SMN1; SMN2KDM4ENTSR1SLC6A7EGLN1
SCHEMBL2365778 0.89 IDH1 (0.35) KMT2AKDM4EMAPTEGLN1DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 LMNA 3668/4885KMT2A 800/4885SMN1; SMN2 3212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.